51
|
Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance. Int J Med Sci 2011; 8:245-53. [PMID: 21487568 PMCID: PMC3074090 DOI: 10.7150/ijms.8.245] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2010] [Accepted: 03/14/2011] [Indexed: 11/05/2022] Open
Abstract
Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.
Collapse
|
52
|
Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011; 31:427-35. [PMID: 21388835 DOI: 10.1016/j.urolonc.2010.08.008] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2010] [Revised: 08/08/2010] [Accepted: 08/10/2010] [Indexed: 12/21/2022]
Abstract
PET- and PET/CT using [(11)C]- and [(18)F]-labeled choline derivates are increasingly being used for imaging of prostate cancer. The value of PET- and PET/CT with [(11)C]- and [(18)F]-labeled choline derivates in biochemical recurrence of prostate cancer has been examined in many studies and demonstrates an increasing importance. PET/CT, in comparison to PET, improves especially the lesion localization as well as characterization. Primary prostate cancer can be detected with moderate sensitivity using PET and PET/CT using [(11)C]- and [(18)F]-labeled choline derivates--the differentiation between benign prostatic hyperplasia, prostatitis, or high-grade intraepithelial neoplasia (HGPIN) is not always possible. At the present time, [(11)C]-choline PET/CT is not recommended in the primary setting but may be utilized in clinically suspected prostate cancer with repeatedly negative prostate biopsies, in preparation of a focused re-biopsy. Promising results have been obtained for the use of PET and PET/CT with [(11)C]- and [(18)F]-labeled choline derivates in patients with biochemical recurrence. The detection rate of choline PET and PET/CT for local, regional, and distant recurrence in patients with a biochemical recurrence shows a linear correlation with PSA value at the time of imaging and reaches about 75% in patients with PSA > 3 ng/ml. Even at PSA values below 1 ng/ml, the recurrence can be diagnosed with choline PET/CT in approximately one-third of the patients. PET and PET/CT with [(11)C]- and [(18)F]-choline derivates can be helpful in the clinical setting for choosing a therapeutic strategy in the sense of an individualized treatment: an early diagnosis of recurrence is crucial to the choice of optimal treatment. Especially important for the choice of treatment is the exact localization of the site of recurrence: local recurrence, recurrence as lymph node metastasis, or systemic recurrence, as it has direct influence on individual therapy. This article reviews the use of PET and PET/CT with [(11)C]- and [(18)F]-labeled choline derivates in prostate cancer imaging with special emphasis on patients with biochemical recurrence. We briefly provide an overview of PET tracers for prostate cancer imaging, the rationale of using choline derivatives for prostate cancer imaging and discuss the contribution of choline PET/CT in patients suffering from prostate cancer with an emphasis on recurrent disease. Furthermore, we provide an outlook on future prospects of choline PET/CT imaging for therapy guidance and monitoring in the framework of therapy individualization.
Collapse
Affiliation(s)
- Bernd Joachim Krause
- Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | | |
Collapse
|
53
|
Lawrence J, Rohren E, Provenzale J. PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. Vet Comp Oncol 2010; 8:163-87. [PMID: 20691025 DOI: 10.1111/j.1476-5829.2010.00218.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Functional imaging using positron emission tomography (PET) plays an important role in the diagnosis, staging, image-guided treatment planning and monitoring of malignant diseases. PET imaging complements conventional anatomical imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). The strength of CT scanning lies in its high spatial resolution, allowing for anatomical characterization of disease. PET imaging, however, moves beyond anatomy and characterizes tissue based on functions such as metabolic rate. Combined PET/CT scanners were introduced commercially in 2001 and a number of technological advancements have since occurred. Radiolabelled tracers such as (18)F-fluorodeoxyglucose (FDG) and (18)F-fluorothymidine (FLT) allow visualization of various metabolic processes within cancer cells. Many studies in human oncology evaluating the utility of PET/CT have demonstrated clinical benefits. Few veterinary studies have been performed, but initial studies show promise for improved detection of malignancy, more thorough staging of canine cancer and determination of early response and disease recrudescence.
Collapse
Affiliation(s)
- J Lawrence
- Department of Small Animal Medicine and Surgery, University of Georgia, College of Veterinary Medicine, Athens, GA 30602, USA.
| | | | | |
Collapse
|
54
|
Shyn PB, Mortele KJ, Britz-Cunningham SH, Friedman S, Odze RD, Burakoff R, Goldberg JE, Erturk M, Silverman SG. Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. J Nucl Med 2010; 51:1841-8. [PMID: 21078803 DOI: 10.2967/jnumed.110.080796] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
UNLABELLED The purpose of this study was to evaluate the diagnostic efficacy of low-dose, combined (18)F-FDG PET/CT enterography (PET/CTE), compared with CT enterography (CTE) alone, in the assessment of patients with Crohn disease. METHODS Thirteen patients with Crohn disease were prospectively enrolled in this pilot study and underwent abdominal-pelvic (18)F-FDG PET/CTE using neutral oral and intravenous contrast medium. The effective dose from PET/CTE was 17.7 mSv for the first 4 patients and 8.31 mSv for the last 9 patients. Six patients underwent surgical resection of the bowel, and 7 patients underwent colonoscopy with biopsies within 27 d (mean, 12 d) of PET/CTE. PET/CTE and CTE images were each visually assessed for Crohn disease involvement in 54 bowel segments with pathology correlation. Extraintestinal findings were recorded. A CTE severity score, maximum standardized uptake value (SUVmax), SUVmax ratio, simplified endoscopic score, and clinical parameters were correlated with pathology inflammation grade, on a per-patient basis and on a per-bowel-segment basis, using Spearman correlation. RESULTS In 3 (23.1%) of 13 patients, (18)F-FDG uptake using PET/CTE revealed active inflammation in a bowel segment not evident using CTE (n = 2) or revealed an enterocolic fistula missed with CTE (n = 1). Visual interpretation of both PET/CTE and CTE images detected the presence of disease in all bowel segments with more than mild inflammation (sensitivity, 100%; specificity, 89.7%; positive predictive value, 78.9%; and negative predictive value, 100%). Correlation to inflammation grade per patient was the strongest for the SUVmax ratio (0.735, P = 0.004) and SUVmax (0.67, P = 0.013), as compared with the CTE score (0.62, P = 0.024). Correlation with inflammation per bowel segment was higher for the CTE score (0.79, P < 0.0001) than the SUVmax ratio (0.62, P < 0.0001) or SUVmax (0.48, P < 0.0001). SUVmax correlated strongly with serum C-reactive protein (0.82, P = 0.023), but CTE score did not. CONCLUSION Low-dose (18)F-FDG PET/CTE, compared with CTE, may improve the detection and grading of active inflammation in patients with Crohn disease. PET/CTE also may reveal clinically significant findings, such as enterocolic fistula, not evident on PET or CTE alone.
Collapse
Affiliation(s)
- Paul B Shyn
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
55
|
Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010; 11:992-1000. [DOI: 10.1016/s1470-2045(10)70088-7] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
56
|
Shin DY, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 2010; 68:165-75. [DOI: 10.1007/s00280-010-1454-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2010] [Accepted: 09/01/2010] [Indexed: 12/20/2022]
|
57
|
Baena Cañada J. Manejando la respuesta terapéutica del tumor con PET. ACTA ACUST UNITED AC 2010; 29:273-4. [DOI: 10.1016/j.remn.2010.07.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Accepted: 07/07/2010] [Indexed: 02/08/2023]
|
58
|
Aboagye EO. The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture. Br J Radiol 2010; 83:814-22. [PMID: 20716650 DOI: 10.1259/bjr/77317821] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Since the days of Sir James MacKenzie Davidson, radiology discoveries have been shaping the way patients are managed. The lecture on which this review is based focused not on anatomical imaging, which already has a great impact on patient management, but on the molecular imaging of cancer targets and pathways. In this post-genomic era, we have several tools at our disposal to enable the discovery of new probes for stratifying patients for therapy and for monitoring response to therapy sooner than is possible using conventional cross-sectional imaging methods. I describe a chemical library approach to discovering new imaging agents, as well as novel methods for improving the metabolic stability of existing probes. Finally, I describe the evaluation of these probes for clinical use in both pre-clinical and clinical validation. The chemical library approach is exemplified by the discovery of isatin sulfonamide probes for imaging apoptosis in tumours. This approach allowed important desirable features of radiopharmaceuticals to be incorporated into the design strategy. A lead compound, [(18)F]ICMT11, is selectively taken up in vitro in cancer cells and in vivo in tumours undergoing apoptosis. Improvement of the metabolic stability of a probe is exemplified by work on [(18)F]fluoro-[1,2-(2)H(2)]choline ("[(18)F]-D4-choline"), a novel probe for imaging choline metabolism. Deuterium substitution significantly reduced the systemic metabolism of this compound relative to that of non-deuteriated analogues, supporting its future clinical use. In order for probes to be useful for monitoring response a number of validation and/or qualification studies need to be performed, including assessments of whether the probe measures the target or pathway of interest in a specific and reproducible manner, whether the probe is stable to metabolism in vivo, what is the best time to assess response with these probes and finally whether changes in radiotracer uptake are associated with clinical outcome. [(18)F]Fluorothymidine, a probe for proliferation imaging has been validated and qualified for use in breast cancer. In summary, the ability to create new molecules that can report on specific targets and pathways provides a strategy for studying response to treatment in cancer earlier than it is currently possible. This could fundamentally change the way medicine is practised in the next 5-10 years.
Collapse
Affiliation(s)
- E O Aboagye
- Comprehensive Cancer Imaging Centre at Imperial College, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
| |
Collapse
|
59
|
Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging. J Thorac Imaging 2010; 25:39-40. [PMID: 20160601 DOI: 10.1097/rti.0b013e3181caa973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
60
|
Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095-105. [PMID: 20215534 DOI: 10.1158/1078-0432.ccr-09-2495] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
PURPOSE To show the relationship between antibody delivery and therapeutic efficacy in head and neck cancers, in this study we evaluated the pharmacokinetics and pharmacodynamics of epidermal growth factor receptor (EGFR)-targeted immunotherapy and radioimmunotherapy by quantitative positron emission tomography (PET) imaging. EXPERIMENTAL DESIGN EGFR expression on UM-SCC-22B and SCC1 human head and neck squamous cell cancer (HNSCC) cells were determined by flow cytometry and immunostaining. Tumor delivery and distribution of cetuximab in tumor-bearing nude mice were evaluated with small animal PET using (64)Cu-DOTA-cetuximab. The in vitro toxicity of cetuximab to HNSCC cells was evaluated by MTT assay. The tumor-bearing mice were then treated with four doses of cetuximab at 10 mg/kg per dose, and tumor growth was evaluated by caliper measurement. FDG PET was done after the third dose of antibody administration to evaluate tumor response. Apoptosis and tumor cell proliferation after cetuximab treatment were analyzed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and Ki-67 staining. Radioimmunotherapy was done with (90)Y-DOTA-cetuximab. RESULTS EGFR expression on UM-SCC-22B cells is lower than that on SCC1 cells. However, the UM-SCC-22B tumors showed much higher (64)Cu-DOTA-cetuximab accumulation than the SCC1 tumors. Cetuximab-induced apoptosis in SCC1 tumors and tumor growth was significantly inhibited, whereas an agonistic effect of cetuximab on UM-SCC-22B tumor growth was observed. After cetuximab treatment, the SCC1 tumors showed decreased FDG uptake, and the UM-SCC-22B tumors had increased FDG uptake. UM-SCC-22B tumors are more responsive to (90)Y-DOTA-cetuximab treatment than SCC1 tumors, partially due to the high tumor accumulation of the injected antibody. CONCLUSION Cetuximab has an agonistic effect on the growth of UM-SCC-22B tumors, indicating that tumor response to cetuximab treatment is not necessarily related to EGFR expression and antibody delivery efficiency, as determined by PET imaging. Although PET imaging with antibodies as tracers has limited function in patient screening, it can provide guidance for targeted therapy using antibodies as delivery vehicles.
Collapse
Affiliation(s)
- Gang Niu
- Imaging Sciences Training Program, Radiology and Imaging Sciences, Clinical Center and National Institute of Biomedical Imaging and Bioengineering, National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, MD20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
61
|
Wehrl HF, Sauter AW, Judenhofer MS, Pichler BJ. Combined PET/MR Imaging — Technology and Applications. Technol Cancer Res Treat 2010; 9:5-20. [DOI: 10.1177/153303461000900102] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The combination of PET and MR in one imaging device has certain advantages over conventional imaging modalities. These include: no additional radiation dose from the MR, superior soft tissue contrast and a multitude of tracers for PET. Certain technical challenges exist when designing a PET/MR system. On the one hand these stem from the presence of the strong MR magnetic field and the addition of PET components to the MR system. Different approaches are presented to overcome these technical obstacles ranging from long optical fibers to systems that use semiconductor light detectors for photon counting. The applications of combined PET/MR are profound in the field of oncology and allow imaging of the four main processes in cancer formation: apoptosis resistance, angiogenesis, proliferation and metastasis. PET/MR has also many clinical and research applications in neurology and cardiology. Alternative techniques such as image fusion, hyperpolarized imaging, 17 O imaging and whole body diffusion are discussed in respect to their relevance regarding PET/MR. Simultaneous multifunctional and anatomical imaging using PET/MR has a great potential to impact biomedical imaging in research and clinic.
Collapse
Affiliation(s)
- H. F. Wehrl
- University of Tuebingen, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Roentgenweg 13, 72076 Tuebingen, Germany
| | - A. W. Sauter
- University of Tuebingen, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Roentgenweg 13, 72076 Tuebingen, Germany
- University of Tuebingen, Department for Diagnostic and Interventional Radiology, Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany
| | - M. S. Judenhofer
- University of Tuebingen, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Roentgenweg 13, 72076 Tuebingen, Germany
| | - B. J. Pichler
- University of Tuebingen, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, Roentgenweg 13, 72076 Tuebingen, Germany
| |
Collapse
|
62
|
Imaging pharmacodynamics in oncology: the potential significance of "flares". Ann Nucl Med 2010; 24:137-47. [PMID: 20069468 DOI: 10.1007/s12149-009-0332-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2009] [Accepted: 11/26/2009] [Indexed: 01/18/2023]
Abstract
The clinical use of (18)F-fluorodeoxyglucose (FDG) positron emission tomography in monitoring anticancer treatment is expanding. At the same time a number of radiotracers aiming to image different aspects of tumour biology such as proliferation and apoptosis are being developed. However, the factors determining changes of radiotracer uptake parameters in response to treatment are not well understood. In many cases, cellularity may be the primary determinant of changes of FDG uptake and may confound the interpretation of metabolic changes. Early imaging assessments have in some cases showed transient increases of uptake parameters, commonly termed "flares", which are likely to be unaffected by cellularity and directly reflect pharmacodynamics at a cellular level. In this review a number of settings where molecular imaging "flares" have been described are discussed. Such changes may often be clinically informative and warrant careful study as potential predictive biomarkers.
Collapse
|
63
|
Abstract
Most anticancer drugs are effective only in subgroups of patients, and our current understanding of tumor biology does not allow us to predict accurately which patient will benefit from a specific therapeutic regimen. Various techniques have, therefore, been developed for monitoring tumor response to therapy, but measuring tumor shrinkage on CT represents the current standard. Although response assessment on CT has been refined over many years, fundamental limitations remain. Interobserver variability in tumor size measurements is still high because of difficulties in delineating tumor tissue from secondary changes in the surrounding tissues. Furthermore, CT is inaccurate in differentiating viable tumor from necrotic or fibrotic tissue. Consequently, the degree of response may be underestimated on CT. Conversely, if tumor shrinkage is short lived and followed by rapid tumor regrowth, CT may overestimate the beneficial effects of a treatment. Finally, CT is limited in characterizing responses in tumors that do not change in size during therapy. Because the growth rate of untreated human tumors varies tremendously, an unchanged tumor size after some weeks of therapy may represent a drug effect but may also indicate a slowly growing tumor that was not affected by the applied therapy. Molecular imaging with PET and the glucose analogue (18)F-FDG PET has been shown to improve response assessment in several tumor types. In malignant lymphoma, international criteria for monitoring response to therapy have recently been revised, and the (18)F-FDG signal now plays a central role in defining tumor response. In a variety of solid tumors, single-center studies have indicated that (18)F-FDG PET may provide earlier or more accurate assessment of tumor response than CT, suggesting that (18)F-FDG PET could play a significant role in personalizing the treatment of malignant tumors. However, generally accepted criteria for response assessment in solid tumors are missing, which makes it frequently impossible to compare the results of different studies. International guidelines and criteria for response assessment by (18)F-FDG PET in solid tumors are, therefore, eagerly awaited.
Collapse
Affiliation(s)
- Wolfgang A Weber
- Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany.
| |
Collapse
|